Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DT3aP-HBs-IPV
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DT3aP-HBs-IPV is a combination vaccine designed to protect against five infectious diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and poliomyelitis. The name indicates the inclusion of three-component acellular pertussis antigens (DT3aP), hepatitis B surface antigen (HBs), and inactivated poliovirus vaccine (IPV). This type of pentavalent or hexavalent vaccine is used primarily in pediatric immunization schedules to reduce the number of injections required for broad protection. The mechanism of action involves stimulating the immune system to produce antibodies against each component pathogen or toxin, thereby conferring immunity without causing disease. These vaccines are typically developed using recombinant DNA technology for hepatitis B antigen and purified toxoids or inactivated pathogens for other components.
- Brand names
- Pediarix
- Other names
- DTaP/Hep B/IPV vaccineDTaP-IPV-HepB vaccine
02
Targets
PV3 (Sabin) (Poliovirus type 3 antigen)HBsAg (Hepatitis B surface antigen)Diphtheria toxin
Beyond the preview
Go deeper on DT3aP-HBs-IPV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DT3aP-HBs-IPV.